Roche scores its first PD-L1 win in China, going straight for SCLC niche
Just weeks after AstraZeneca’s Imfinzi became the first and only approved PD-L1 drug in China, regulators have ushered in Roche’s Tecentriq to the checkpoint frenzy.
The Swiss pharma giant is going straight for a niche that it knows well: extensive-stage small cell lung cancer. Per its estimates, two thirds of SCLC patients have reached this phase by the time they are diagnosed, leading to a poor prognosis and an average 5-year survival rate of 2% despite the use of chemo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
